Fisiopatología de GIST

El equipo de voluntarios de la Fundación se dio a la tarea de desarrollar este increible video que nos explica sobre la formación de un tumor del estroma gastrointestinal.

  • GIST Awareness Day logo NEW

GIST Awareness Day 2020 – Spain

Colectivo GIST Espańa celebró el Día de Concienciación de GIST (GIST Awareness Day) con una publicación sobre el tema. A pesar de todo el trabajo realizado por las asociaciones de pacientes, por los [...]

  • GIST Awareness Day logo NEW

GIST Awareness Day 2020 – Colombia

Fundación GIST Colombia & Fundación SIMMON & AlianzaGIST promoted awareness about gastrointestinal stromal tumors on GIST Awareness Day. GIST Awareness Day was created by the Life Raft [...]

  • GIST Awareness Day logo NEW

GIST Awareness Day 2020 – Mexico

Fundación GIST México celebrated GIST Awareness Day with these actitivities: Spot on local radio. "GISTJuntos" This spot which was broadcast 4 times a day from July 8th to [...]

  • GIST Awareness Day logo NEW

GIST Awareness Day 2020 – UK

GIST Cancer UK celebrated GIST Awareness Day by sharing stories of patient and clinicians. GIST Awareness Day was created by the Life Raft Group in 2014 to bring awareness and public attention to gastrointestinal stromal tumors and raise funds for #GISTresearch.

  • GIST Awareness Day logo NEW

GIST Awareness Day 2020 – Chile

GIST Chile celebrated GIST Awareness Day 2020 with the themes #GISTHope and #GISTJuntos (GIST Together). You can find GIST Chile on Facebook - https://www.facebook.com/gistchile, Twitter - @GistChile, Insta - gist_chile. GIST Awareness Day was [...]

  • GIST Awareness Day logo NEW

GIST Awareness Day 2020 – India

Friends of Max (FOM), led by Viji Venkatesh,  enthusiastically celebrated GIST Awareness Day 2020 with a plethora of posts and patient stories as well as patient meetings.

  • Deciphera Pharmaceuticals logo

Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.

Core Values